SHERP

Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study

Cited 0 time in webofscience Cited 34 time in scopus
Authors
Koo, Bon-Kwon; Kim, Yong-Seok; Park, Kyung-Woo; Yang, Han-Mo; Kwon, Dong-A; Chung, Jin-Wook; Hahn, Joo-Yong; Lee, Hae-Young; Park, Jin-Shik; Kang, Hyun-Jae; Cho, Young-Seok; Youn, Tae-Jin; Chung, Woo-Young; Chae, In-Ho; Choi, Dong-Ju; Oh, Byung-Hee; Park, Young-Bae; Kim, Hyo-Soo
Issue Date
2007-08-21
Publisher
Elsevier
Citation
Lancet. 2007 Aug 18;370(9587):567-74.
Keywords
Aged*Angioplasty, Transluminal, Percutaneous CoronaryAntineoplastic Agents, Phytogenic/administration & dosageCoronary Restenosis/pathology/*prevention & controlCyclooxygenase Inhibitors/administration & dosage/adverseeffects/*therapeutic useDisease-Free SurvivalDrug Therapy, CombinationFemaleHumansKaplan-Meiers EstimateMaleMiddle AgedPaclitaxel/administration & dosageProspective StudiesPyrazoles/administration & dosage/adverse effects/*therapeutic useStents/*adverse effectsSulfonamides/administration & dosage/adverse effects/*therapeutic use
Abstract
BACKGROUND: In-vitro and animal experiments have shown that the cyclo-oxygenase 2 inhibitor celecoxib can reduce formation of neointima within stents. We aimed to test whether celecoxib has similar effects in a clinical setting. METHODS: In a randomised two-centre trial, we enrolled 274 patients who had angina pectoris or a positive stress test and who had native coronary artery lesions for which implantation of paclitaxel-eluting stents was feasible. All patients were given aspirin (100 mg daily) and clopidogrel (75 mg daily). 136 patients were randomly assigned to receive celecoxib (400 mg before the intervention, and 200 mg twice daily for 6 months after the procedure). The primary endpoint was late luminal loss on quantitative coronary angiography at 6 months after the intervention. Secondary endpoints were cardiac death, non-fatal myocardial infarction, and revascularisation of the target lesion. Analysis was done on a modified intention-to-treat basis. This study is registered with ClinicalTrials.gov, number NCT00292721. FINDINGS: At 6 months, mean in-stent late luminal loss was lower in the celecoxib group (0.49 mm, SD 0.47) than in the control group (0.75 mm, 0.60) (absolute difference 0.26 mm; 95% CI 0.12-0.40). Frequency of secondary outcomes at 6 months was also lower in the celecoxib group, mainly because of a reduced need for revascularisation of the target lesion. INTERPRETATION: These data suggest that the adjunctive use of celecoxib for 6 months after stent implantation in patients with coronary artery disease is safe and can reduce the need for revascularisation of the target lesion.
ISSN
1474-547X (Electronic)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17707751

http://hdl.handle.net/10371/13498
DOI
https://doi.org/10.1016/S0140-6736(07)61295-1
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Emergency Medicine (응급의학전공)Journal Papers (저널논문_응급의학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse